Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prithviraj Bose

Showing results (11-20 of 224) with videos related to

Pageof 23
Sort By:
Expert Opinion on Investigational Drugs|November 2, 2016
Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasmsPrithviraj Bose, Srdan Verstovsek
Expert Opinion on Pharmacotherapy|November 8, 2016
Myelofibrosis: an update on drug therapy in 2016Prithviraj Bose, Srdan Verstovsek
Therapeutic Advances in Hematology|September 14, 2019
Updates in the management of polycythemia vera and essential thrombocythemiaPrithviraj Bose, Srdan Verstovsek
Leukemia Research|July 6, 2014
Orphan drug designation for pracinostat, volasertib and alvocidib in AMLPrithviraj Bose, Steven Grant
Clinical Lymphoma, Myeloma & Leukemia|August 2, 2017
Developmental Therapeutics in Myeloproliferative NeoplasmsPrithviraj Bose, Srdan Verstovsek
Blood|May 14, 2017
JAK2 inhibitors for myeloproliferative neoplasms: what is next?Prithviraj Bose, Srdan Verstovsek
Cancer|October 13, 2024
Ruxolitinib for myelofibrosis: The earlier, the better?Prithviraj Bose, Pankit Vachhani
Hemasphere|September 9, 2020
JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future PerspectivesPrithviraj Bose, Srdan Verstovsek
Faculty Reviews|March 15, 2021
Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitorsPrithviraj Bose, Varsha Gandhi
Journal of Clinical Medicine|June 27, 2015
Rational Combinations of Targeted Agents in AMLPrithviraj Bose, Steven Grant
Pageof 23

Showing results (11-20 of 224) with videos related to

Sort By:
Pageof 23
Expert Opinion on Investigational Drugs|November 2, 2016
Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasmsPrithviraj Bose, Srdan Verstovsek
Expert Opinion on Pharmacotherapy|November 8, 2016
Myelofibrosis: an update on drug therapy in 2016Prithviraj Bose, Srdan Verstovsek
Therapeutic Advances in Hematology|September 14, 2019
Updates in the management of polycythemia vera and essential thrombocythemiaPrithviraj Bose, Srdan Verstovsek
Leukemia Research|July 6, 2014
Orphan drug designation for pracinostat, volasertib and alvocidib in AMLPrithviraj Bose, Steven Grant
Clinical Lymphoma, Myeloma & Leukemia|August 2, 2017
Developmental Therapeutics in Myeloproliferative NeoplasmsPrithviraj Bose, Srdan Verstovsek
Blood|May 14, 2017
JAK2 inhibitors for myeloproliferative neoplasms: what is next?Prithviraj Bose, Srdan Verstovsek
Cancer|October 13, 2024
Ruxolitinib for myelofibrosis: The earlier, the better?Prithviraj Bose, Pankit Vachhani
Hemasphere|September 9, 2020
JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future PerspectivesPrithviraj Bose, Srdan Verstovsek
Faculty Reviews|March 15, 2021
Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitorsPrithviraj Bose, Varsha Gandhi
Journal of Clinical Medicine|June 27, 2015
Rational Combinations of Targeted Agents in AMLPrithviraj Bose, Steven Grant
Pageof 23